Atomoxetine May Aid Memory in Older Women By David Douglas 本文翻译自[Medscape] http://www.medscape.com/viewarticle/737791?src=rss NEW YORK (Reuters Health) Feb 22 - Atomoxetine may improve subjective attention and reduce memory difficulties in perimenopausal and postmenopausal women, researchers report in a February 2nd online paper in Menopause. 根据 The Journal of Menopause 二月份发表的研究指出：更年期与停经後的妇女使 用atomoxetin，可能可以增进注意力的集中和降低记忆力下降的问题。 　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　 Dr. C. Neill Epperson told Reuters Health by email that "subjective declines in memory, focus and organization are common in mid-life women. We believe that the results of our small randomized clinical trial provide proof-of-concept that atomoxetine may improve subjective memory, attention and concentration." Dr. C. Neil Epperson表示：「记忆力障碍的问题常见於中年妇女，我们相信此次的 小型随机分配的临床试验之结果，将为atomoxetin用於提升记忆力、注意力和专注力 的角色，提供一个观念性验证(proof-of-concept, 请指点要怎麽翻比较好!!)的佐证。」 "These findings will need to be confirmed in a larger randomized clinical trial before clinical recommendations can be made. However, women who are concerned about memory changes in mid-life may wish to discuss the results of this study with their doctor," he added. Dr. C.N. Epperson接着说：「此次实验的结果仍须要其他更大型的临床试验以进行确 认（sample size的确是不够大...）。然而，关心本身记忆衰退问题的中年女性们， 仍可能会希望与其医师讨论此实验的结果。」 Dr. Epperson of the University of Pennsylvania School of Medicine, Philadelphia, and colleagues sought to determine the effect of the drug in 16 women with memory complaints but no history of attention-deficit/hyperactivity disorder (ADHD) or other psychiatric disorders. 菲律宾Pennsylvania大学医学院的Dr. Epperson收纳了16位有记忆问题困扰，且没有 任何"注意力不集中/过动症(ADHD)"病史或其他精神疾病病史的女性，以评估药物对记 忆的效果。 They were enrolled in a double-blind, placebo-controlled crossover study of atomoxetine 80 mg/day during two 6-week treatment periods separated by a 4-week washout period. 本实验设计为：双盲交叉试验(placebo vs. atomoxetine 60 mg/day) 共各有六周的投药 or 安慰剂的treatment periods 　　　　　　　中间的washout period为四个礼拜 The Brown Attention Deficit Disorder Scale (BADDS) was used to systematically elicit self-report of perceived cognitive difficulties in executive function. This 40-item measure asks respondents to use a scale of 0-3 (where 0 = "no problem or never" and 3 = "kind of a big problem or almost every day"). Mean baseline score was 37.9 in all participants and 42.3 in the 12 who completed both arms of the study. 受试者皆以BADDS进行自我认知评量。这份量表有40项目，每个项目依受试者主观判 定程度填写 0-3 分 ( 0 = 没问题/从不 ; 3 = 噢这是个大问题~/这每天都在发生) 。所有受试者的平均基准受测质为37.9分，而在完成整个试验的12位受试者的基准受 测值则为42.3分。 BADDS scores fell to 25.5 with atomoxetine, a significant difference (p = .009). Although scores decreased to 30.1 under placebo, the difference from baseline wasn't significant (p= .2). 实验结果： 　　　 　 BADDS of Baseline BADDS of Post-treatment p-value Atomoxetine 42.3 25.5 0.009* Placebo 42.3 30.1 0.2 There was no observable effect on levels of depression or anxiety with atomoxetine. 在药物不良反应方面，本次试验并没有发现在atomoxetine的受试者中，有发生显着 的忧郁或焦虑的副作用。 "Such research could be useful to test whether self-report elicited with ADHD rating scales may capture midlife-onset cognitive impairments of women that may not be captured adequately by neuropsychological tests," say the investigators. 试验执行者表示：「本次试验发现，对於一些在神经精神科学检测上无法测量，但利 用自我问卷评估方式，却能有效监测中年认知功能失常之女性患者，一个有效的评估 方式。」 这个效度与信度　可能需要其他实验设计来佐证... They also suggest that higher doses of atomoxetine and "studies using other medications approved for treatment of ADHD in adults might also be useful" in such patients. 作者亦提到：「更高剂量的atomoxetine可能是有效的。」 　　　　　　「其他被核准用於治疗ADHD的药物，对此类病患可能也是有效的。」 The study was funded by an investigator-initiated grant from Eli Lilly & Company and in part by the National Institute of Mental Health. 本试验由Eli Lill药厂和国家精神健康研究机构赞助执行 Menopause. Posted online February 2, 2011 Abstrate Link: http://0rz.tw/ULk9X 感冒吃药了 昏昏沉沉暂时睡不着　 就献丑翻了翻这篇 (有哀凤真的蛮好用的~) 如有错误或不足 请大家不吝指教 谢谢大家 -- ~老化的四个徵兆~ ○ zzzz ！ * \○/ ★ 　　 (○ ？ └□ " ○□═ □ 　　□> √√ ╦══╦ ∥ 　　|\ 坐着一直睡 躺着睡不着 旧的一直提 说过就忘记 --

※ 发信站: 批踢踢实业坊(ptt.cc) ◆ From: 118.170.197.51